|
Orthologous residues
|
|
EGFR (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
B82 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Src (mouse)
|
co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
Zn(2+)
|
|
|
|
increase
|
|
|
Zn(2+), PP1
|
|
|
|
inhibit treatment-induced increase
|
|
|
EGF, PP1
|
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|